TP53 and neuroblastoma: The use of MDM2-p53 antagonists represents a potential novel therapeutic strategy in neuroblastoma, where the incidence of p53 mutations is much lower in comparison to adult malignancies and p53 mutations are rare even at relapse (reviewed by [13]).